Kancera AB (Nasdaq First North Premier Growth Market: KAN) announces that screening of covid-19 patients for the clinical phase II study of KAND567 starts today. The study, which is carried out in collaboration with Capio St. Göran's Hospital and Petter Brodin's research group at SciLifeLab, aims to study the effect of KAND567 on the immune system, lung function and rehabilitation. Results from the study will be analyzed and communicated on two occasions, the first after all patients have undergone sampling after day 7, and the second after day 90.

Kancera develops drugs that counteract damage in acute and chronic inflammation. The Fractalkine blocker KAND567 is primarily developed to effectively counteract hyper-inflammation in various disease states and thereby protect vital organs, e.g. in connection with heart attacks and severe viral infections. The Phase II study involving 40 covid-19 patients documents the effects of oral administration of KAND567 or placebo over seven days in combination with the best standard of care. A follow-up health check and sampling takes place after the end of treatment and after 90 days in order to follow the rehabilitation. During the study, strictly objective analyzes of treatment effect are performed, including measures of oxygen saturation and respiratory capacity. In addition, a detailed survey of immunological regulation is carried out at cell and gene level.

 

About Kancera AB (publ)
Kancera develops drugs that counteract damage from acute and chronic inflammation. Fraktalkine blocker KAND567 is developed primarily to effectively counteract hyperinflammation in various medical conditions and thus protect vital organs, e.g. in connection with heart attacks and severe viral infections. Kanceras has during the third quarter 2020 started a phase II clinical study in covid-19 patients. In the second half of 2020, a second application for authorisation is planned for a phase II clinical study in patients with myocardial infarction. Since scientific studies have shown increased activity for the fractalkine system not only in connection with myocardial infarction but also in several other inflammatory conditions and certain forms of cancer, there are several possible development routes for Kancera’s fraktalkine blockers KAND567 and KAND145. Kancera AB conducts research and development within Karolinska Institutet Science Park in Stockholm. The share is traded on NASDAQ First North Premier. FNCA Sweden AB is the company's Certified Adviser. FNCA can be reached on info@fnca.se and on 08-528 00 399. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin and Professor Håkan Mellstedt are all scientific advisors and board members of Kancera AB.

For further information, please contact,

Thomas Olin, CEO: +46-735-20 40 41

Kancera AB (publ)
Karolinska Institutet Science Park
Nanna Svartz Väg 4
SE 171 65 Solna
Please visit the company's website; https://www.kancera.com